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The epidermal growth factor system has been associated to prognosis in patients with bladder cancer based mainly on the expression
of the epidermal growth factor (EGF) receptor 1 (EGFR) and HER2 and their activating ligands. Since limited information exists
concerning the expression of other parts of the EGF system, we examined the expression of the receptors HER3 and HER4 and their
activating ligands, the heregulins (HRGs), in bladder cancer patients. Biopsies from bladder cancer tumours were obtained from 88
patients followed for a median of 23 months (range, 1–97 months). The mRNA content of four ligands and their isoforms (HRG1a,
HRG1b, HRG2a, HRG2b, HRG3 and HRG4) and two receptors (HER3 and HER4) was quantified by real-time PCR. A significantly
lower mRNA expression level of HER3 (P¼0.0003), HRG2a (P¼0.0159), HRG2b (P¼0.0007) and HRG4 (Po0.0001) was
observed in muscle-invasive (T2–T4) tumours as compared to superficial (Ta) tumours. The expression of HER3 mRNA correlated
strongly to overall survival (P¼0.0042); increased expression of HER4 (P¼0.0261) and HRG4 (P¼0.0245) was also associated with
better prognosis. Interestingly, patients with coexpression of HER3 (P¼0.0034) or HER4 (P¼0.0080) together with their stimulating
ligand HRG4 showed even better survival than for HER3 or HER4 alone. Our results together with previous data suggest a dual face
for the EGF system. While it is well established that an increased signalling through HER1 and HER2 is related to a poor prognosis,
our data suggest that signalling through HER3 and HER4 is related to a favourable outcome in bladder cancer patients.
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Bladder cancer is the fifth most common cancer in men and ninth
in women (Droller, 1998). Despite much research on the topic, it is
still difficult to predict tumour progression, optimal therapy and
clinical outcome (Stein et al, 1998; Burchardt et al, 2000). Tumour
staging is considered to be the best prognostic marker, but several
other markers including the presence of members of the epidermal
growth factor (EGF) family have been suggested (Kristensen et al,
1988; Mellon et al, 1996; Ravery et al, 1997; Vollmer et al, 1998).
The EGF family consists of four receptors, HER1 (human EGF
receptor 1, also known as EGFR, HER2 (ErbB2), HER3 (ErbB3) and
HER4 (ErbB4). For HER2, no ligand has so far been described, and
HER3 is characterised by its impaired kinase function (Guy et al,
1994). The ligands for these receptors consist of approximately 20
different proteins encoded by at least 10 different genes (Gullick,
2001; Yarden and Sliwkowski, 2001). The numerous EGF family-
specific ligands include EGF and five other ligands able to bind to
HER1, whereas the heregulins (HRGs) are the ligands for HER3
and HER4. Currently there are four known HRG genes, HRG1,
HRG2, HRG3 and HRG4. HRG1 and HRG2 include multiple
splicing isoforms, and these are denoted as either alpha or beta
isoforms depending on the sequence of the EGF homology domain,
which is a sequence element conserved among all the HRGs and
characterised by its homology to sequences in EGF.
Previous studies have indicated that the EGF system plays an
important role in bladder cancer. Among the four EGF receptors,
HER1, HER2 and their activating ligands show a positive
correlation with tumour stage in transitional carcinoma of the
bladder (Neal et al, 1985; Messing et al, 1987; Thogersen et al,
2001). The same holds for a number of other types of malignancies,
which within the last years has led to the development of a new
treatment strategy aimed to inhibit signalling through HER1 or
HER2 (de Bono and Rowinsky, 2002; Kubo et al, 2003; Lammering
et al, 2003; Rowinsky, 2003). However, the role of HER3 and HER4
in human tumours is at present unclear. Conflicting reports on this
topic have been published, as some have emphasised that HER3
and HER4 correlate with poor prognosis in human breast cancer
(Bieche et al, 2003), while others have shown that HER3 and HER4
elevated expressions are associated with a better prognosis in this
disease (Pawlowski et al, 2000). However, in the case of HER4, the
few clinical studies carried out so far have suggested that its
expression is associated with favourable prognosis (Thybusch-
Bernhardt et al, 2001; Suo et al, 2002) and recently it has been
reported that HER4 mediates ligand-dependent antiproliferative
and differentiation responses in human breast cancer cells (Earp
et al, 2003). The binding of HRG to its receptors induces either
HER3 or HER4 to form homodimers or heterodimers mostly with
HER2, thus triggering diverse signalling cascades (Bacus et al,
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y1992). Heregulin can regulate a variety of responses in cultured
cells, including proliferation, differentiation and survival (Burden
and Yarden, 1997). In AU565 and MDA-MB-453 human breast
cancer cells, a low concentration of HRG is mitogenic, whereas a
higher concentration leads to differentiation and inhibition of cell
growth (Bacus et al, 1992). Current studies suggest that HRGs also
initiate programmed cell death and induce cell differentiation (Le
et al, 2000, 2002). Although much progress has been achieved in
understanding HRG-induced signalling, the expression of HRGs
and their prognostic significance in cancer patients has not been
examined, most likely because of limitation in available methods.
Epidermal growth factor family gene expression can reliably be
studied at the mRNA level, and based on a number of studies the
expression is likely to reflect the presence of the corresponding
protein (Knowlden et al, 1998; Walker and Dearing, 1999; Suo et al,
2002; Junttila et al, 2003).
In this report, we investigate the mRNA expression of HER3,
HER4, HRG1, HRG2, HRG3 and HRG4 genes, including the splice
variants from HRG1 and HRG2, in biopsies from 88 bladder cancer
patients using the real-time RT–PCR method. In contrast to HER1
and HER2 and their activating ligands (Thogersen et al, 2001), we
report that an increased expression of HER3 and HER4 and their
activating ligands is related to a favourable prognosis.
MATERIALS AND METHODS
Patients
A total of 88 patients with primary bladder cancer were included.
Biopsies were obtained by transurethral tumour resection. Tumour
stage was assigned according to the Union Internationale Contre le
Cancer Tumor-Node-Metastasis system (Spiessl et al, 2003).
Grading was performed in accordance with the methods described
by Bergkvist et al (1965). The relationships between the distribu-
tion of tumour stage, age and sex are presented in Table 1. Patients
were allocated into three groups depending on tumour stage: Ta,
superficial tumours; T1, superficial invasive tumours; and T2–T4,
muscle-invasive tumours. At the time of inclusion, 18 patients had
received treatment in the form of radical radiotherapy, che-
motherapy or intravesical therapy with bacillus Calmette–Guerin.
The follow-up period was from the date of biopsy to the day of
death or to December 2003. Patients were censored if they were
alive at the time of analysis (December 2003). The median follow-
up was 23 months (range, 1–97 months). The regional committee
of Scientific Ethics, Aarhus approved the study, and the
procedures were followed in accordance with the Helsinki
Declaration.
Cell lines
We analysed two bladder cancer cell lines RT4 (derived from grade
I tumour) and T24 (derived from grade III tumour), obtained from
the American Tissue Type Culture Collection (ATCC). Cells were
cultured in McCoy’s 5A modified medium, supplemented with
10% fetal calf serum, in T25 culture flasks (Nunc) in a humidified
atmosphere containing 5% CO2. Cells were checked routinely for
Mycoplasma infection (Mycoplasma PCR kit (Roche)). Cells were
harvested at 90B95% confluence, and washed twice with PBS
(137mM NaCl, 2.7mM KCl, 10mM Na2HPO4 and 2mM KH2PO4,p H
7.4) and placed in a denaturing solution as described below.
Preparation of total RNA
Tumour samples or cultured cells used for mRNA analysis were
immediately placed in a denaturing solution (4moll
 1 guanidine
thiocyanate, 25mmoll
 1 sodium citrate (pH 7), 0.5% sarkosyl and
0.1mmoll
 1 2-mercaptoethanol) and stored at  801C. A frozen
biopsy (o20mg) was homogenised by a Heidolph Diax 600 mixer.
Total RNA was extracted from tissues according to a slightly
modified method of Chomczynski and Sacchi (1987). The RNA was
resuspended in diethyl pyrocarbonate-treated double-distilled
water and stored at  801C. RNA was quantified using a UV
spectrophotometer (A260nm¼1 corresponds to 40mgml
 1 RNA).
Real-time RT–PCR quantification of mRNA
Quantification of mRNA was performed by real-time RT–PCR on
the Lightcycler instrument (Roche). Primer sequences, annealing
temperature and PCR products size for the components of the EGF
family are presented in Table 2. We conducted BLASTN searches
to confirm the specificity of the nucleotide sequences chosen for
the primers. Specificity was further verified by checking the size of
the product by agarose gel electrophoresis and nucleotide
sequencing using a 310 genetic analyser (Applied Biosystems)
and BigDye Terminator Technology.
cDNA was generated in a reverse transcription reaction where
1mg RNA was mixed with 2.5U AMW reverse transcriptase
(Applied Biosytems) in a reaction mixture containing 10mM Tris-
HCL (pH 8.3), 1Uml
 1 RNase inhibitor, 1mmoll
 1 deoxyribonu-
cleoside triphosphate (dATP, dTTP, dGTP, dCTP), 2.5mmoll
 1 16-
mer d(T)16 primer, 50mmoll
 1 KCl and 6.25mmoll
 1 MgCl2 in a
total volume of 20ml (all reagents from Applied Biosystem). The
Table 1 Clinical data
Tumour stage Ta T1 T2–T4
Patient (no.) 21 18 49
Sex
Male 11 17 41
Female 10 1 8
Age
Median 69 74 68
Range 53–88 60–88 54–83
Table 2 Primer sequences and primer conditions
mRNA species
(amplicon size) Gene-specific primers (sense/antisense) (primer conc./annealing temperature) External calibrator
HER3 365bp 50-GGT GCT GGG CTT GCT TTT-30 50-CGT GGC TGG AGT TGG TGT TA-30 (5pmol/651C) HEC
HER4 265bp 50-TGT GAG AAG ATG GAA GAT GGC-30 50-GTT GTG GTA AAG TGG AAT GGC-30 (5pmol/651C) KLE
HRG1a 179bp 50-ATC CAC CAC TGG GAC A-30 50-TTT GGA TCA TGG GCA-30 (5pmol/601C) KLE
HRG1b 321bp 50-TAG GAA ATG ACA GTG CCT C-30 50-CGT AGT TTT GGC AGC GA-30 (5pmol/651C) KLE
HRG2a 308bp 50-AAA TAT GGC AAC GGC AG-30 50-CGC AAA GGC AGT TTC T-30 (5pmol/601C) KLE
HRG2b 236bp 50-GCT TTA CGT CAA CAG CG-30 50-CCG GTG TAT CCC ACA G-30 (5pmol/631C) HCV
HRG3 256bp 50-ACA GTG CAA GCG AAA AC-30 50-CAC TAT GAT ATG AGG GCG-30 (5pmol/611C) KLE
HRG4 107bp 50-CTGTTGTCTGCGGTATTC-30 50-TCATTCTTGGTCAAGAGAGT-30 (5pmol/611C) RT4
Beta-actin 313 50-GGCGGCACCACCATGTACCCT-30 50-AGGGGCCGGACTCGTCATACT-30 (15pmol/681C) KLE
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90s at 941C followed by 30min at 421C and finally at 941C for
1min. This cDNA preparation was used for real-time PCR of all
RNA species examined. Reverse transcription of all samples to
cDNA was performed on the same day. Real-time PCR was
performed with the Lightcycler Syber Green I quantification kit
(Roche) in a total volume of 10ml in LC glass capillaries (Roche).
Real-time PCR was conducted with the following profile: initial
heating to 941C for 90s followed by 40–50 PCR cycles of heating to
941C, incubation for 5s at the annealing temperature specific for
each mRNA species (Table 2) and incubation for 10s at 721C. The
fluorescence data were collected and the mRNA quantified with
lightcycler software version 3.3 by using the second derivative
maximum method of quantification. A standard melting curve was
used to check the quality of amplification. A calibration curve and
positive and negative controls were included in each run. The
calibration curve was composed of serial dilutions of a pool of
culture cell lines RNA for each mRNA species (Table 2). To
generate the calibration curve, calibrators with the following
concentration of RNA were used: 1, 0.5, 0.25, 0.1, 0.05, 0.025, 0.01,
0.005 and 0.0025mgml
 1. Positive control (in duplicate) was
included in each run together with negative control, which was a
sample without RNA added. As different calibrator are used for
each gene and the expression is presented as relative expression to
a specific calibrator, the levels of expressions are not comparable
across different genes. Variation could exist in the amount of total
RNA added to each reaction mix and in its quality. We therefore
quantified transcripts of beta-actin as an endogenous RNA control,
and each sample was normalised on the basis of its beta-actin
mRNA contents. Beta-actin has been used as control gene in
various studies on bladder cancer (Vageli et al, 1996; Chiu et al,
2002) as well as in breast cancer (Agudo et al, 2004). All the
quantifications in this study are presented as the ratio between the
target gene and beta-actin.
Statistical analysis
Nonparametric tests were used throughout this study. Two-sided
P-values less than 0.05 were considered to be significant. The
Mann–Whitney U-test and Kruskal–Wallis test were used to
compare the expression of the EGF family members with clinical
stage, grade, tumour type and size of the tumour. Correlations
were analysed using Spearman’s rank correlation test. Life table
calculations were performed using the Kaplan–Meier method.
Comparison between the curves was carried out using log-rank
test. (The software Graph Pad Prism (version 4) was used for
statistical analysis.)
RESULTS
mRNA expression of HER3, HER4 and the HRGs
The mRNA expression of two receptors, HER3 and HER4, and four
ligands (HRG1–4), including the a and b isoforms of HRG1 and
HRG2, was quantified in biopsies from 88 bladder cancer patients
(Table 1) and two bladder cancer cell lines (RT4, derived from
grade I; and T24, derived from grade III). Expression of the
receptors HER3 and HER4, and ligands HRG1a, HRG1b, HRG2a,
HRG2b, HRG3 and HRG4 was detected in 99, 63, 90, 61, 63, 43, 75
and 91% of the bladder cancer cases, respectively. The median
concentrations of receptors were as follows: HER3 (median Ta
(10.38), T1 (5.10), T2–T4 (2.72)) and HER4 (median Ta (0.012), T1
(0.009), T2–T4 (0.0)). The median concentrations of ligands were
as follows: HRG1a (median Ta (0.04), T1 (0.022), T2–T4 (0.08)),
HRG1b (median Ta (0.024), T1 (0.013), T2–T4 (0.03)), HRG2a
(median Ta (2.22), T1 (0.41), T2–T4 (0.45)), HRG2b (median Ta
(3.07), T1 (0.0), T2–T4 (0.0)), HRG3 (Ta (0.82), T1 (0.20), T2–T4
(0.81)) and HRG4 (median Ta (40.91), T1 (7.20), T2–T4 (13.76))
(Figure 1). The differences were highly significant for HER3
HRG4
P < 0.0001
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Figure 1 mRNA expression of HER3 (A), HER4 (B) and their ligands HRG1a (C), HRG1b (D), HRG2a (E), HRG2b (F), HRG3 (G) and HRG4 (H)i n
88 human biopsy samples. Horizontal dashed lines show the median cutoff (median of all samples) used for survival analysis. Median cutoff for HRG2b was
zero and samples were categorised as no HRG2b expression (low) or HRG2b-positive expression (high). Solid horizontal lines demonstrate the median of
each individual group. All data are shown as the ratio between the target gene and beta-actin. *P-value, nonparametric Kruskal–Wallis test.
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y(Pp0.0002), HRG2b (Pp0.0005) and HRG4 (Pp0.0001) (Figure
1A, F and H). The expression level of HRG2b (Pp0.001) and HRG4
(Pp0.001) was also altered in biopsies classified as T1 in
comparison with Ta (Figure 1F and H), which shows an early
loss of HRG2b and HRG4 during bladder cancer progression. The
median concentration of HER4, HRG1a, HRG1b and HRG3 did not
show any significant difference among three groups (Figure 1).
Our results in two bladder cancer cell lines RT4 and T24, which
have been used as models of superficial noninvasive and invasive
tumours, respectively (Theodorescu et al, 1990, 1998; Redwood
et al, 1992; Booth et al, 1997; Davies et al, 1999), show a similar
pattern of mRNA expression as in bladder cancer biopsies, except
for HRG3. The mRNA expression level of HER3 (P¼0.0022),
HRG2b (P¼0.0440), HRG3 (P¼0.0090) and HRG4 (0.0001) was
significantly downregulated in T24 compared to RT4 (Figure 2A–
H). Only for HRG3, which shows no change in expression in
biopsy samples, all other mRNA expression results in bladder
cancer cell lines are in agreement with the results obtained from
biopsies.
Correlation with clinical and histopathological parameters
HER3 and HRG4 downregulation is strongly correlated with stage
(T2–T4 compared to Ta), grade (IIIþIV compared to I) and type
of the tumour (solid compared to papillary type) (Table 3).
Similarly, reduced expression of HRG2b is correlated with higher
stage and grade of the tumour but not with tumour type. Finally,
HRG2a mRNA level is only correlated with tumour stage. The
mRNA expression of HER4, HRG1 (a and b) and HRG3 is not
correlated with any of the clinical and pathological parameters of
the tumours (Table 3).
Inter-relationship between HER3, HER4 and their
stimulating ligands
Using the Spearman’s rank correlation test (Table 4), we found the
strongest positive correlation between mRNA content of HER3 or
HER4/HRG4 (Po0.0001) followed by HER3/HRG2b and HER3 or
HER4/HRG2a. The strongest negative correlation was observed for
HER3/HRG1a followed by HER3/HRG1b.
Correlation with survival
We examined the correlation between survival and the expression
of individual members of the EGF family. For this part of the study,
the median concentrations of each mRNA examined from the
bladder tumours were selected as the cutoff point dividing all the
patients into two groups, one with high expression (above median)
and another with low expression (below median). Finally, the
prognostic significance of coexpression of receptors (HER3 and
HER4) with their ligands (HRG1–4) was examined. Tumours were
categorised into high and low groups using the same median
concentration as cutoff (as described above). Only those tumours
showing low (below median) or high (above median) mRNA level
for both the receptor and ligand were included in this part of the
analysis.
Kaplan–Meier survival curves were made to evaluate the impact
of ligand and receptor expression in context to survival of the
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Figure 2 mRNA expression of HER3 (A), HER4 (B) and their ligands HRG1a (C), HRG1b (D), HRG2a (E), HRG2b (F), HRG3 (G) and HRG4 (H)i n
RT4 (derived from grade 1) and T24 (derived from grade 3) bladder cancer cell lines. Error bars represent standard deviation of at least four experiments.
All data are shown as the ratio between the target gene and beta-actin.
Table 3 Correlation between EGF family mRNA levels and clinico-
pathological parameters of bladder cancer
Genes Stage
a Grade
b Tumour type
c Size
d
HER3 0.0003
e 0.0017 0.0002 NS
HER4 NS NS NS NS
HRG1a NS NS NS NS
HRG1b NS NS NS NS
HRG2a 0.0159 NS NS NS
HRG2b 0.0007 0.0279 NS NS
HRG3 NS NS NS NS
HRG4 o0.0001 0.0016 0.0138 NS
aTa vs T2–T4.
bI+II vs III+IV.
cPapillary vs solid type tumour.
dTumour size o3cmvs
43cm.
eP-value (Mann–Whitney U-test); NS, not significant.
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ypatients (Figure 3A–H). HER3 mRNA expression showed a highly
significant correlation to survival (P¼0.0042, w
2¼8.18). Similarly,
longer survival was observed in patients with elevated expression
of HER4 (P¼0.0261, w
2¼4.948) and HRG4 (P¼0.0245,
w
2¼5.062). Interestingly, coexpression of HER4 together with its
stimulating ligand HRG4 (P¼0.0080, w
2¼7.04) showed even
better correlation to survival than mRNA expression of HER4
alone (compare Figure 3B with Figure 4B). In contrast to HER4,
HER3 prognostic value was not greatly affected by HRG4
coexpression (compare Figure 3A with Figure 4A). No other
receptor–ligand combinations correlated with the survival better
than their expression alone. The HER4–HRG4 was found to be the
best among all combinations analysed in this study.
DISCUSSION
For the first time, data on the mRNA expression of all known
HRGs and the HER3 and HER4 receptors, which they activate, are
presented and related to the prognosis of bladder cancer patients.
We have found an association between low HER3, HRG2b and
HRG4 mRNA expressions and markers of tumour aggressiveness.
More importantly, we have shown that HER3 and HER4 expression
is a better prognostic indicator in bladder cancer patients than any
other EGF family member analysed in this study, especially when
coexpressed with HRG4.
The function of HER3 as a prognostic indicator is controversial
based on the few studies performed on human tumours. Chow et al
(2001) have suggested that the HER2 and HER3 expression profile
is associated with favourable prognosis in bladder cancer patients,
which is in agreement with the findings in the present study. In
addition, HER3 expression is also associated with better prognosis
in breast cancer (Pawlowski et al, 2000) and oral squamous cell
carcinoma (Xia et al, 1999). In contrast, Witton et al (2003) have
shown that high expression of HER3 is associated with poor
prognosis in breast cancer patients. Discrepancies in the results of
the few studies available so far justify further research into the role
of HER3 in bladder and other cancers. However, our data support
that high HER3 expression indicates better survival in patients
with bladder cancer.
It is important to note that HER4 expression did not correlate
with any of the clinical or pathological variables of the tumour.
However, as mentioned before, its expression correlated with
survival of bladder cancer patients, especially when coexpressed
with HRG4. These results are consistent with the studies in bladder
cancer (Chow et al, 2001) and most of the reports in breast cancer
(Knowlden et al, 1998; Suo et al, 1998, 2001; Kew et al, 2000),
showing HER4 expression to be a good prognostic indicator. In
addition, studies of breast cancer cell lines have demonstrated that
the antiproliferative and differentiation responses of HER4 are
HRG dependent and correlate with HER4 activation (Sartor et al,
2001). HRG4 is a ligand for HER4 but not for the other three EGF
receptors (Hobbs et al, 2002). Therefore, it is not surprising that
HER4 when coexpressed with HRG4 shows significantly better
prognostic value than its expression alone (Figures 3B and 4B).
Therefore, it is important to consider expression of receptor as
well as expression of the ligand when evaluating the final outcome
of the disease and survival of patients. Our results suggest that
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Figure 3 Kaplan–Meier survival curves for 88 bladder cancer patients plotted for HER3 (A), HER4 (B), HRG1a (C), HRG1b (D), HRG2a (E), HRG2b
(F), HRG3 (G) and HRG4 (H). In all of the groups, the patients were categorised into low (below median) and high (above median).
Table 4 Relationship between HER3, HER4 and their ligands, the
heregulins
HER3 HER4
HRG1a  0.316
a  0.153
0.0027
b NS (0.15)
HRG1b  0.270  0.145
0.0109 NS (0.18)
HRG2a +0.318 +0.237
0.0026 0.0256
HRG2b +0.290 +0.064
0.0060 NS (0.54)
HRG3  0.036 +0.082
NS (0.73) NS (0.44)
HRG4 +0.498 +0.473
o0.0001 o0.0001
aSpearman’s correlation coefficient.
bP-value, spearman’s rank correlation test; NS,
not significant.
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survival than their individual expression and can identify a
subgroup of patients who possibly may benefit from treatment
directed towards the interaction between HER4 and HRG4.
Prognostic value of HER3 and HER4 was further analysed in
samples from patients with tumours classified as T1–T4. We
demonstrate that a high expression of HER3 correlates to survival
and almost reaches significance (P¼0.0887). Interestingly, a
significant correlation with increased survival is found in patients
with high expression of both HER3 and HER4 (P¼0.0399) (data
not shown). However, HER4 expression alone did not correlate
significantly to survival in this group of patients (P¼0.3125).
Recently, Junttila et al (2003) have analysed the expression of all
four EGF receptors in bladder cancer cell lines and in bladder
cancer biopsies. They have shown that the level of HER3 and HER4
was decreased in grade II (5637) and grade III (T24) bladder
cancer cell lines, which is in keeping with our results on cell lines.
In addition, they show that, compared to nonmalignant bladder
samples, 50% of their 18 tumour samples express higher amount of
HER3 and HER4. In addition, the study demonstrates that HER3
and HER4 mRNAs can reliably be quantified with real-time PCR.
In the present study, we extend these results, and demonstrate a
prognostic significance of the HER3 and HER4 receptors and their
ligands, the HRGs.
HRG4 is relatively a new member of the EGF family and to our
knowledge there is no report available showing any relationship
between malignancies and HRG4. The HRG4 gene is distinct from
the other three HRGs, suggesting a unique physiological role for
HRG4 (Harari et al, 1999). Here, we present HRG4 as a novel
prognostic marker for bladder cancer patients, especially when
coexpressed with HER4. Additional investigations are required to
elucidate the biological role of HRG4 and its relationship with
other EGF family receptors and ligands.
We have noticed a significant loss of HRG2b mRNA expression
in biopsies from invasive tumours (T1 and T2–T4) compared to
superficial noninvasive tumours (Ta). However, no correlation was
found between HRG2b expression and patient survival. HRG2b is a
potent agonist for HER3 and HER4 (Hobbs et al, 2002). The impact
of HRG2b in bladder cancer development and its prognostic
significance is not known. However, by using MDA-MB-231 breast
cancer cells, cocultured with endothelial cells, Nakano et al (2004)
have shown that HRG2 is involved in an inhibitory effect on
angiogenesis in vitro as well as in vivo. Therefore, it is possible that
early loss of HRG2b during tumour development attenuates
signalling through HER3 or HER4 and escalates cellular growth
and angiogenesis, which ultimately leads to tumour progression
and metastasis.
Our results indicate strong positive correlation between the
mRNA expression levels of two receptors (HER3 and HER4) and
ligands HRG2 and HRG4. There is also a negative correlation
between HRG1 and HER3. These results concur with previous
observations suggesting different roles for the HRGs. For example
in MDA-MB-468 human mammary tumour cells, HRG2b inhibits
cell growth, whereas HRG1b does not (Crovello et al, 1998). HRG1
also plays an important modulatory role in glioma cell invasion
(Ritch et al, 2003). In addition, although not statistically
significant, we have shown that high HRG1b expression correlates
to poor survival in bladder cancer patients (Figure 3D), which is in
accordance with recent findings in breast cancer showing that
HRG1 is a key promoter of tumorigenicity and metastasis (Tsai
et al, 2003). Together, these data suggest that HRG1 is functionally
distinct from HRG2 and HRG4 and that the cell-type-specific
effects of HER3 and HER4 resulting in proliferation or differentia-
tion may relate to their stimulating ligands.
In order to explore whether the changes observed in bladder
cancer biopsies were also reflected in cancer cell lines, we studied
two bladder cancer cell lines representing grade 1 (RT4) and grade
III (T24) tumours. Our results indicate that these cell lines have the
same expression pattern as in biopsy samples except for one of the
six HRGs studied, HRG3. These findings suggest that RT4 and T24
cells could be a useful model system for superficial and invasive
tumours from bladder, respectively.
In conclusion, we report that HRGs are expressed in variable
levels in bladder cancer and mRNA expressions of HER3, HRG2b
and HRG4 are decreased in muscle-invasive tumours as compared
to superficial tumours. Moreover, we report that increased ex-
pression of HER3, HER4 and HRG4 correlates to a better survival
of patients with bladder cancer. Our results suggest that
coexpression of HER3 and HER4 together with HRG4 shows
better prognostic value than any of the other studied EGF family
member alone.
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